Trial Profile
A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Rett syndrome
- Focus Registrational; Therapeutic Use
- Acronyms ARCH
- Sponsors Jazz Pharmaceuticals Inc
- 11 Feb 2021 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped:The study was terminated due to enrollment challenges and the COVID-19 pandemic.
- 13 Nov 2020 Status changed from suspended to active, no longer recruiting.
- 11 May 2020 According to a GW Pharmaceuticals media release, recruitment temporarily on hold due to COVID-19 crisis